Enzyme News and Research

RSS

Nine research projects awarded access to PRACE Research Infrastructure

Nine research projects, two from Germany, two from Spain and one each from France, Hungary, the Netherlands, Portugal and the UK, have been awarded access to the PRACE Research Infrastructure. In total 362.8 Million compute core hours were granted for the JUGENE, IBM BlueGene/P, hosted by the Gauss-Centre for Supercomputing member site in Jülich, Germany, which is the first Petascale HPC system available to researchers through PRACE.

10 Nov 2010

UC Davis researchers identify new pathway to repair oxidative-damaged DNA

UC Davis researchers have found a new pathway for repairing DNA damaged by oxygen radicals. The results are published this week in the journal Proceedings of the National Academy of Sciences.

10 Nov 2010

Synageva's SBC-102 enzyme replacement therapy for LAL deficiency granted European orphan product designation

Synageva BioPharma Corp., a privately held biopharmaceutical company, announced that the European Medicines Agency (EMA) granted orphan product designation for SBC-102 (Recombinant Human Lysosomal Acid Lipase), the Company's enzyme replacement therapy in development to treat Lysosomal Acid Lipase (LAL) Deficiency.

10 Nov 2010

DHA protects brain tissue and promotes recovery in acute ischemic stroke

Research led by Dr. Nicolas Bazan, Boyd Professor, Villere Chair, and Director of the Neuroscience Center of Excellence at LSU Health Sciences Center, has shown that Docosahexaenoic acid (DHA), a component of fish oil, is a powerful therapeutic agent that can protect brain tissue and promote recovery in an experimental model of acute ischemic stroke, even when treatment is delayed by up to five hours.

9 Nov 2010

ORVACS launches ERAMUNE 01 Phase II study to decrease HIV viral reservoirs

ORVACS has launched a Phase II study designed to test the hypotheses that combination therapy with potent antiviral agents and immunomodulator can lead to a decrease in the HIV viral reservoirs and, ultimately, to eradication of the virus. The study is currently being conducted at clinical sites in France, Spain, Italy, and the United Kingdom.

9 Nov 2010

Statins do not reduce risk for colorectal cancer in postmenopausal women

The use of statins among a group of postmenopausal women did not reduce the risk for colorectal cancer, according to the results of a prospective analysis of data from the large population-based Women's Health Initiative (WHI).

9 Nov 2010

Raptor initiates dosing in DR Cysteamine Phase 2 clinical trial for Huntington's Disease

Raptor Pharmaceutical Corp., today announced that the first patient has been dosed in its Phase 2 clinical trial of DR Cysteamine for the potential treatment of Huntington's Disease. The Phase 2 clinical trial is being conducted under a previously announced collaboration agreement with The Centre Hospitalier Universitaire d'Angers ("CHU d'Angers"), which has commenced enrolling patients at eight clinical sites throughout France.

8 Nov 2010

Positive results from Ardea's RDEA594 combination study with febuxostat or allopurinol for gout

Ardea Biosciences, Inc. announced positive results from two clinical studies of RDEA594 in combination with currently marketed drugs for the treatment of gout patients, febuxostat (Uloric®) and allopurinol.

8 Nov 2010

Blocking beta glucuronidase enzyme could eliminate side effects of CPT-11 in colon cancer treatment

A debilitating side effect of a widely used but harshly potent treatment for colon cancer could be eliminated if a promising new laboratory discovery bears fruit.

8 Nov 2010

MitoSciences awarded $244,000 grant under IRS Qualifying Therapeutic Discovery Project

MitoSciences Inc. today announces that it has been awarded a $244,000 grant under the IRS Qualifying Therapeutic Discovery Project. This award was made in support of MitoSciences' efforts to develop the world's most advanced set of assays for unlocking the role of metabolism in cancer and other critical diseases, and for helping researchers to design and monitor the most effective therapies for those conditions.

8 Nov 2010

New findings could help scientists devise optimal therapies for Friedreich's ataxia

Scripps Research Institute scientists have taken a step closer to understanding the cause of Friedreich's ataxia, a debilitating neurological condition that affects tens of thousands of people worldwide, and so far has no cure.

8 Nov 2010

TRPM7 protein plays a key role in maintenance of magnesium homeostasis

An international team led by researchers at the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School has published new findings that demonstrate how a specific protein controls the body's ability to balance magnesium levels. Magnesium is an essential element for good health and is critical to more than 300 biochemical reactions that occur in the body.

8 Nov 2010

Agios receives two grants under QTDP program to develop novel cancer metabolism therapies

Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the rapidly emerging field of cancer metabolism, today announced it has received two grants totaling more than $488,000 from the Qualifying Therapeutic Discovery Project (QTDP) Program.

8 Nov 2010

New radiotracer application may advance understanding of estrogen-related diseases

A study at the U.S. Department of Energy's (DOE) Brookhaven National Laboratory has demonstrated that a molecule "tagged" with a radioactive form of carbon can be used to image aromatase, an enzyme responsible for the production of estrogen, in the human brain. The research, published in the November issue of Synapse, also uncovered that the regions of the brain where aromatase is concentrated may be unique to humans.

4 Nov 2010

Millennium and Takeda initiate TAK-700 Phase III clinical trial in advanced prostate cancer

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced the initiation of a Phase III clinical trial for TAK-700 in the U.S. in patients with advanced prostate cancer. TAK-700 is a selective, oral, non-steroidal androgen synthesis inhibitor that in preclinical studies has been shown to selectively bind to and inhibit the enzyme 17,20 lyase in both the testes and adrenal glands.

4 Nov 2010

Study links positive well-being to higher telomerase activity

Positive psychological changes that occur during meditation training are associated with greater telomerase activity, according to researchers at the University of California, Davis, and the University of California, San Francisco. The study is the first to link positive well-being to higher telomerase, an enzyme important for the long-term health of cells in the body.

4 Nov 2010

Single injection of morphine to fight persistent pain reduces testosterone level: Research

A single injection of morphine to fight persistent pain in male rats is able to strongly reduce the hormone testosterone in the brain and plasma, according to a new paper published in Molecular Pain.

4 Nov 2010

Synageva receives $2.3 million under QTDP program

Synageva BioPharma Corp., a privately held biopharmaceutical company developing novel treatments for rare diseases, today announced that the US Treasury Department awarded approximately $2.3 million to Synageva BioPharma as part of the Qualifying Therapeutic Discovery Project Program.

4 Nov 2010

Top 10 Medical Innovations for 2011

From pill-sized cameras to radioactive compounds that let doctors "see" inside a patient's brain, Cleveland Clinic's Top 10 Medical Innovations for 2011 showcases new techniques, therapies and approaches to treating a host of diseases.

3 Nov 2010

Curemark awarded QTDP grant to advance development of CM-AT for autism

Curemark LLC, a drug research and development company focused on the treatment of neurological diseases, announced today that it has been awarded a grant by the United States government under the Qualifying Therapeutic Discovery Project (QTDP) Program to advance the development of its lead product CM-AT for autism. CM-AT is presently in Phase III clinical trials at 18 sites around the US.

3 Nov 2010

Enzyme News and Research

Nine research projects awarded access to PRACE Research Infrastructure

UC Davis researchers identify new pathway to repair oxidative-damaged DNA

Synageva's SBC-102 enzyme replacement therapy for LAL deficiency granted European orphan product designation

DHA protects brain tissue and promotes recovery in acute ischemic stroke

ORVACS launches ERAMUNE 01 Phase II study to decrease HIV viral reservoirs

Statins do not reduce risk for colorectal cancer in postmenopausal women

Raptor initiates dosing in DR Cysteamine Phase 2 clinical trial for Huntington's Disease

Positive results from Ardea's RDEA594 combination study with febuxostat or allopurinol for gout

Blocking beta glucuronidase enzyme could eliminate side effects of CPT-11 in colon cancer treatment

MitoSciences awarded $244,000 grant under IRS Qualifying Therapeutic Discovery Project

New findings could help scientists devise optimal therapies for Friedreich's ataxia

TRPM7 protein plays a key role in maintenance of magnesium homeostasis

Agios receives two grants under QTDP program to develop novel cancer metabolism therapies

New radiotracer application may advance understanding of estrogen-related diseases

Millennium and Takeda initiate TAK-700 Phase III clinical trial in advanced prostate cancer

Study links positive well-being to higher telomerase activity

Single injection of morphine to fight persistent pain reduces testosterone level: Research

Synageva receives $2.3 million under QTDP program

Top 10 Medical Innovations for 2011

Curemark awarded QTDP grant to advance development of CM-AT for autism

Biochemistry eBook

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest Life Science News